PT - JOURNAL ARTICLE AU - Mei, Yang AU - Weinberg, Samuel E. AU - Zhao, Lihui AU - Frink, Adam AU - Qi, Chao AU - Behdad, Amir AU - Ji, Peng TI - Risk stratification of hospitalized COVID-19 patients through comparative studies of laboratory results with influenza AID - 10.1101/2020.05.18.20101709 DP - 2020 Jan 01 TA - medRxiv PG - 2020.05.18.20101709 4099 - http://medrxiv.org/content/early/2020/05/22/2020.05.18.20101709.short 4100 - http://medrxiv.org/content/early/2020/05/22/2020.05.18.20101709.full AB - Background The outbreak of coronavirus disease 2019 (COVID-19) in December 2019 overlaps with the flu season.Methods We compared clinical and laboratory results from 719 influenza and 973 COVID-19 patients from January to April 2020. We compiled laboratory results from the first 14 days of the hospitalized patients using parameters that are most significantly different between COVID-19 and influenza and hierarchically clustered COVID-19 patients based on these data. The clinical outcomes were compared among different clusters.Findings Temporal analyses of laboratory results revealed that compared to influenza, patients with COVID-19 exhibited a continued increase in the white blood cell count, rapid decline of hemoglobin, more rapid increase in blood urea nitrogen (BUN) and D-dimer, and higher level of alanine transaminase, C-reactive protein, ferritin, and fibrinogen. Using these results, we sub-classified the COVID-19 patients into 5 clusters through a hierarchical clustering analysis. We then reviewed the medical record of these patients and risk stratified them based on the clinical outcomes. The cluster with the highest risk showed 27ยท8% fatality, 94% ICU admission, 94% intubation, and 28% discharge rates compared to 0%, 38%, 22%, and 88% in the lowest risk cluster, respectively. Patients in the highest risk cluster had leukocytosis including neutrophilia and monocytosis, severe anemia, increased red blood cell distribution width, higher BUN, creatinine, D-dimer, alkaline phosphatase, bilirubin, and troponin.Interpretation There are significant differences in the clinical and laboratory courses between COVID-19 and influenza. Risk stratification in hospitalized COVID-19 patients using laboratory data could be useful to predict clinical outcomes and pathophysiology of these patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was partially supported by National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK124220) and National Heart, Lung, and Blood Institute (R01 HL148012). P.J. is a scholar of the Leukemia and Lymphoma Society and the Harrington Discovery Institute.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesN/A